Search results

226 results

Sorted by Date . Sort by Relevance

Guidance Remove Guidance filter
Awaiting development Remove Awaiting development filter
Proposed Remove Proposed filter
Technology appraisal guidance Remove Technology appraisal guidance filter
Interventional procedures guidance Remove Interventional procedures guidance filter
Social care guidelines Remove Social care guidelines filter
Medical technologies guidance Remove Medical technologies guidance filter
Clinical guidelines Remove Clinical guidelines filter
Diagnostics guidance Remove Diagnostics guidance filter

Atezolizumab for adjuvant treatment of renal cell carcinoma with a high risk of metastasis [ID5101]

Awaiting development [GID-TA11000] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]

Awaiting development [GID-TA10972] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]

Awaiting development [GID-TA11013] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion-positive advanced non-small-cell lung cancer [ID5110]

Awaiting development [GID-TA11023] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

Awaiting development [GID-TA11018] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over [ID 5107]

Awaiting development [GID-TA11017] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID 5072]

Awaiting development [GID-TA10960] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Talquetamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5082]

Awaiting development [GID-TA10969] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5073]

Awaiting development [GID-TA10959] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID 5096]

Awaiting development [GID-TA11007] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Teclistamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID 5087]

Awaiting development [GID-TA10968] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]

Awaiting development [GID-TA10967] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Maribavir for cytomegalovirus infection after haematopoietic stem cell transplant [ID 5075]

Awaiting development [GID-TA10958] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID 5077]

Awaiting development [GID-TA10971] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab with chemoradiation for untreated locally advanced cervical cancer [ID 5081]

Awaiting development [GID-TA10963] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID 5102]

Awaiting development [GID-TA11010] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer [ID 5113]

Awaiting development [GID-TA11025] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Benralizumab for treating eosinophilic oesophagitis in people aged 12 to 65 [ID 5093]

Awaiting development [GID-TA10995] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID 5097]

Awaiting development [GID-TA11011] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID 5114]

Awaiting development [GID-TA11026] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID 5076]

Awaiting development [GID-TA10961] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people 1 to 17 years [ID 5104]

Awaiting development [GID-TA11006] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Etrasimod for previously treated moderately to severely active ulcerative colitis [ID 5091]

Awaiting development [GID-TA10991] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Zanubrutinib for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID 5078]

Awaiting development [GID-TA10964] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID 5085]

Awaiting development [GID-TA10962] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Zanubrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID 5079]

Awaiting development [GID-TA10966] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

Awaiting development [GID-TA10998] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Paclitaxel with encequidar for treating advanced breast cancer [ID 5111]

Awaiting development [GID-TA11022] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab for neoadjuvant and adjuvant treatment of resectable stage 2 to 3B non-small-cell lung cancer [ID 5094]

Awaiting development [GID-TA11002] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID 5103]

Awaiting development [GID-TA11004] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID 5112]

Awaiting development [GID-TA11020] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID 5109]

Awaiting development [GID-TA11024] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica [ID 5105]

Awaiting development [GID-TA11016] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID 5092]

Awaiting development [GID-TA10994] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Rucaparib for maintenance treatment of newly diagnosed platinum-sensitive ovarian, fallopian tube or peritoneal cancer [ID 5100]

Awaiting development [GID-TA10999] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites (ID1278)

Awaiting development [GID-TA10279] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

Awaiting development [GID-TA11033] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]

Awaiting development [GID-TA10900] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000]

Awaiting development [GID-TA10899] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Daridorexant for treating insomnia disorder [ID3774]

Awaiting development [GID-TA10888] Expected publication date: 16 August 2023

Type

Technology appraisal guidance

Status

Awaiting development
OrganOx metra for preserving livers for transplant [ID5516]

Awaiting development [GID-TA11035] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]

Awaiting development [GID-TA10660] Expected publication date: 26 September 2022

Type

Technology appraisal guidance

Status

Awaiting development
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947

Awaiting development [GID-TA10834] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Vutrisiran for hereditary transthyretin amyloidosis [ID5074]

Awaiting development [GID-TA10954] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]

Awaiting development [GID-TA10855] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens [ID3951]

Awaiting development [GID-TA10889] Expected publication date: 14 September 2022

Type

Technology appraisal guidance

Status

Awaiting development
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]

Awaiting development [GID-TA10909] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Test347

Awaiting development [GID-TA10949] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]

Awaiting development [GID-TA10723] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development
LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]

Awaiting development [GID-TA10728] Expected publication date: TBC

Type

Technology appraisal guidance

Status

Awaiting development